NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted ...

ProMIS Neurosciences (PMN) announced that the Company will present preclinical data on computationally-derived vaccines for neurodegenerative ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of ...

The New Mexico Office of the Medical Investigator says Hackman died from a cardiovascular disease with Alzheimer's being a contributing factor. Sign up for our Newsletters The Alzheimer's Association ...

The following resolution were passed at the extraordinary general meeting (the "EGM") of Alzinova AB (publ) ("the Company") on 7 March 2025 in Gothenburg. Long-term incentive program (LTIP 2025:1 for ...

Around 4 million tons of nylon 6,6 (a type of synthetic polyamide) are produced annually, making it one of the most commonly ...

Peptide therapeutics, such as GLP-1a (glucagon-like peptide-1 agonists), offer promising treatments for weight control and ...

Molecular modelling encompasses all theoretical methods and computational techniques used to mimic and study the structure and behaviour of molecules, ranging from small chemical systems to large ...

Zervimesine is an investigational oral, once-daily pill being developed for the treatment of CNS diseases, including Alzheimer disease and dementia with Lewy bodies.